The Taiwan Stock Exchange (TWSE) Board of Directors approved two major life science listings on the 20th, signaling continued momentum for the "Innovation Board" and medical AI sectors.

• aetherAI (雲象科技): Specialized in digital pathology and medical AI, the company’s application for listing 88.85 million shares on the Taiwan Innovation Board (TIB) was approved. aetherAI is a leader in transforming pathological slides into structured data for clinical decision support.
• StemCyte (永笙-KY): A primary listing (KY) for 192.47 million shares was approved. StemCyte is a global player in umbilical cord blood hematopoietic stem cells and advanced cell therapy, with a long-term focus on regenerative medicine and transplant applications.

Resource: 雲象科技、永笙拚上市 證交所董事會通過